NC-stat | DPNCheck™

NC-stat® | DPNCheck™
 

 

 


 


 

 

 



 

Fast, accurate and quantitative test that may be used
to evaluate peripheral neuropathies such as DPN
(diabetic peripheral neuropathy).

The problem: diabetic peripheral neuropathy (DPN)*
  • Over 200M people worldwide have diabetes
  • There are 24M people in the US with diabetes,
    and 57M have pre-diabetes
  • DPN affects 60-70% of people with diabetes
  • DPN causes pain, falling and foot ulcers which may lead
    to amputation
  • The annual direct cost of DPN in the US is estimated at $11B1

    *National Diabetes Fact Sheet, 2007. Centers for Disease Control.

The unmet need: detection, confirmation, and
monitoring of DPN
  • Physicians often under diagnose DPN leading to missed
    opportunities to intervene2
  • The American Diabetes Association (ADA) recommends
    annual screening and monitoring for DPN3
  • The most widely used DPN detection tool is the 5.07/10g monofilament, which identifies late stage neuropathy4
  • Many people with diabetes do not  receive annual neuropathy
    testing and foot exams5
  • There is a need for a widely available, objective and
    standardized test for DPN

The solution: NC-stat | DPNCheck
  • Fast, accurate and quantitative test that may be used
    to evaluate systemic neuropathies such as DPN
  • May aid in the early detection, confirmation, and
    monitoring of DPN
  • Measures sural nerve conduction velocity and response amplitude - standard biomarkers for asymptomatic and
    clinical DPN
  • Sensitive and specific for DPN6,7, and predictive of
    its complications8
  • Straightforward clinical interpretation
  • Compact and ergonomic hand-held device designed
    for ease-of-use
  • Single patient use biosensors 
  • Cost effective

For more information on NC-stat|DPNCheck review the FAQs below:

Clinical & Technical FAQ
Sural Nerve Conduction FAQ
Reimbursement FAQ


References

1. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The healthcare costs of diabetic peripheral neuropathy in the US. Diabetes Care. Jun 2003;26(6):1790-1795.
2. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care. Jun 2005;28(6):1480-1481.
3. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. Apr 2005;28(4):956-962.
4. Dros J, Wewerinke A, Bindels PJ, van Weert HC. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Ann Fam Med. Nov-Dec 2009;7(6):555-558.
5. Kirkman MS, Williams SR, Caffrey HH, Marrero DG. Impact of a program to improve adherence to diabetes guidelines by primary care physicians. Diabetes Care. Nov 2002;25(11):1946-1951.
6. Perkins BA, Grewal J, Ng E, Ngo M, Bril V. Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. Diabetes Care. Sep 2006;29(9):2023-2027.
7. Perkins BA, Orszag A, Grewal J, Ng E, Ngo M, Bril V. Multi-site testing with a point-of-care nerve conduction device can be used in an algorithm to diagnose diabetic sensorimotor polyneuropathy. Diabetes Care. Mar 2008;31(3):522-524.
8. Pambianco, et al. Risk factor associations with clinical distal symmetrical polyneuropathy and various neuropathy screening instruments and protocols in type 1 diabetes. Diabetes Res Clin Pract.. 2011;91.